NASDAQ: FBRXForte Biosciences Inc Stock
$9.96+0.28 (+2.89%)
Updated Jul 17, 2025
FBRX Price
$9.96
Fair Value Price
$7.63
Market Cap
$65.57M
52 Week Low
$4.11
52 Week High
$28.68
P/E
-1.05x
P/B
1.71x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$43.71M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.24
Operating Cash Flow
-$34M
Beta
0.84
Next Earnings
Aug 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
FBRX Overview
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine FBRX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
FBRX
Ranked#232 of 472
Ranked#232 of 472
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.36 | A | |
| $9.07 | A | |
| $18.91 | A |
Be the first to know about important FBRX news, forecast changes, insider trades & much more!
FBRX News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how FBRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FBRX ($9.96) is overvalued by 30.56% relative to our estimate of its Fair Value price of $7.63 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
FBRX ($9.96) is not significantly undervalued (30.56%) relative to our estimate of its Fair Value price of $7.63 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
FBRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more FBRX due diligence checks available for Premium users.
Valuation
FBRX fair value
Fair Value of FBRX stock based on Discounted Cash Flow (DCF)
Price
$9.96
Fair Value
$7.63
Overvalued by
30.56%
FBRX ($9.96) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
FBRX ($9.96) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
FBRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
FBRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.05x
Industry
-193.15x
Market
31.25x
FBRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.71x
Industry
4.63x
FBRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FBRX's financial health
Profit margin
Revenue
$0.0
Net Income
-$15.7M
Profit Margin
0%
FBRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$47.5M
Liabilities
$9.0M
Debt to equity
0.24
FBRX's short-term assets ($47.16M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FBRX's short-term assets ($47.16M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FBRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
FBRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.4M
Investing
$36.3M
Financing
-$2.3M
FBRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FBRX vs Biotech Stocks
Forte Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.